NTHI
NeOnc Technologies Holdings, Inc. (NASDAQ)
Healthcare — Biotechnology
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
Price History
Fundamentals
| Market Cap | $115.66M |
| P/E Ratio (TTM) | - |
| Forward P/E | -5.92 |
| EPS (TTM) | $-1.80 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $16.00 |
| Analysts | 3 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 48.6 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $12.99 |
| 52-Week Low | $3.69 |
| 50-Day Avg | $4.87 |
| 200-Day Avg | $7.99 |
| Avg Volume | 99.8K |
| Volume | 67.3K |
Performance Analysis
NEUTRALNTHI presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:23 UTC
Back to Screener Export Report